Belite Bio (BLTE) Common Equity (2021 - 2026)

Belite Bio's Common Equity history runs 6 years deep, the most recent figure standing at $795.8 million for Q1 2026.

• On a quarterly basis, Common Equity rose 403.44% year-over-year to $795.8 million in Q1 2026; TTM through Mar 2026 was $795.8 million, a 403.44% increase from a year earlier, with the FY2025 full-year figure at $770.5 million, up 428.38% from the prior year.
• Common Equity grew to $795.8 million in Q1 2026 per BLTE's latest filing, from $770.5 million in the prior quarter.
• Across five years, Common Equity topped out at $795.8 million in Q1 2026 and bottomed at $35.2 million in Q1 2023.
• The 5-year median for Common Equity is $113.4 million (2024), against an average of $206.6 million.
• Biggest YoY gain for Common Equity was 428.38% in 2025; the steepest drop was 30.8% in 2025.
• Year by year, Common Equity stood at $41.5 million in 2022, then surged by 117.9% to $90.4 million in 2023, then soared by 61.25% to $145.8 million in 2024, then soared by 428.38% to $770.5 million in 2025, then grew by 3.28% to $795.8 million in 2026.
• Per Business Quant, the three latest BLTE Common Equity figures stand at $795.8 million (Q1 2026), $770.5 million (Q4 2025), and $274.1 million (Q3 2025).